News | January 06, 2026
Nia Therapeutics unveils first implantable brain interface for memory disorders
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
Pravesh brings with him over 29 years of experience in leading complex manufacturing operations and driving operational excellence
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
India’s pharmaceutical sector stands at a pivotal inflection point
The state-of-the-art laboratory opens at the Corewell Health Southfield Center in early 2027
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Subscribe To Our Newsletter & Stay Updated
